MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
An Interview With Anthony J. Comerota, MD
Dr. Comerota discusses protocol for DVT and PE treatment, as well as opportunities for attendees of the first ISVS meeting this March.
Expert Roundtable
Featuring Anthony J. Comerota, MD; Marc H. Glickman, MD, FACS; Thomas A. Hennebry, MB BCh BAO, FACC, FSCAI; Charles Pollack, MD, MA; and Mahmood K. Razavi, MD
Introduction
By Anthony J. Comerota, MD
An Inappropriate and Unproven Option
Matching DVT Patients With Procedures: Endovascular, Surgical, and Hybrid Options
Dr. Anthony J. Comerota discusses experiences treating patients who have challenging venous occlusions and the therapies that are currently available.
Venous Disease Care: Improving Training Paradigms
How to ensure that physicians receive comprehensive training in venous and lymphatic disorders.
By Steven E. Zimmet, MD, and Anthony J. Comerota, MD
Intermittent Pneumatic Compression for DVT Prophylaxis
Which device characteristics and hemodynamic metrics are important for physicians to consider in making the best patient-specific treatment decisions?
By Anthony J. Comerota, MD, FACS, FACC
Cook’s Zilver Vena Stent Shows Sustained High Patency in 3-Year VIVO Study Results
October 29, 2024—Cook Medical announced that findings from the VIVO clinical study of the company’s Zilver Vena venous self-expanding stent demonstrated high rates of patency sustained for 3 years.
Venous Solutions
By Mark A. Turco, MD, FACC
Chief Medical Editor's Page
VTE Therapy
By Barry T. Katzen, MD
VIVO Trial Will Evaluate Cook's Zilver Vena Stent to Treat Iliofemoral Venous Obstruction
April 11, 2013—Cook Medical (Bloomington, IN) announced the launch of the VIVO clinical research study to evaluate the safety and effectiveness of the Zilver Vena venous self-expanding stent in the treatment of symptomatic iliofemoral venous outflow obstruction.
New Messages, New Media: ATTRACT Study Update
Renewing the commitment to find the best possible treatment for future DVT patients.
By Suresh Vedantham, MD
The Best Answers Come From the Hardest Questions . . . So Keep Asking ‘Em
C-TRACT Trial: Coming Together to Tackle Chronic DVT
Why C-TRACT is needed, its study design, and how current endovascular practitioners can support it.
CAS in Asymptomatic Patients at High Risk for CEA: Rebuttals
By Jay S. Yadav, MD
By Krishna J. Rocha-Singh, MD, FACC, FAHA, FSCAI, FSVM, Guest Chief Medical Editor
Guidelines for the Use of Optional (Retrievable and Convertible) Vena Cava Filters
A summary of the SIR multidisciplinary consensus statement.
By John A. Kaufman, MD
Playing Offense in Postthrombotic Syndrome: The C-TRACT Trial Opportunity
Why a randomized controlled trial is important to evaluate iliac vein stenting in PTS and how the C-TRACT trial can help resolve unanswered questions.
2-Year ATTRACT Data: Anticoagulation Alone Best for Most DVT; PCDT Benefits Seen in Certain Iliofemoral Patients
March 6, 2017—The much-anticipated 2-year results from the ATTRACT study were presented by Suresh Vedantham, MD, FSIR, on behalf of the trial’s investigators, at the 2017 Society of Interventional Radiology (SIR) Annual Scientific Meeting.
Current Trends in Venous Stenting
Stenting expert Gerard O'Sullivan, MD, shares his thoughts on practice preferences and what's in store for the future of this treatment strategy.
